Study guide

Biopsychosocial Development, Pubertal Staging, and Adolescent Communication

EBP-EAP Examination in Paediatrics Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Governance, Ethics & Child Safeguarding

EBP-EAP Format, Delivery, Scoring, and Clinical Vignette Strategy Paediatric Ethics, Consent/Assent, Gillick Competence, and Patient Safety Child Protection, Physical/Emotional Abuse, Neglect, and Non-Accidental Injury (NAI)

2 Chapter 2: Neonatal Transition, Resuscitation & Prematurity

Delivery Room Care, Apgar Scoring, and Neonatal Resuscitation Algorithm Respiratory Distress Syndrome (RDS), Surfactant Therapy, and Bronchopulmonary Dysplasia Perinatal Asphyxia, HIE Sarnat Staging, and Therapeutic Hypothermia Protocol

3 Chapter 3: Neonatal Morbidities, Jaundice & Congenital Infections

Unconjugated vs Conjugated Hyperbilirubinemia, Phototherapy Thresholds, and Exchange Transfusion Early- vs Late-Onset Sepsis, Group B Streptococcus, and Congenital TORCH Infections NEC Diagnosis/Bell Staging, Neonatal Hypoglycaemia, and Newborn Bloodspot Screening

4 Chapter 4: Acute Paediatric Emergencies & Critical Care

EPLS/PALS Structured Approach, Types of Shock, and Weight-Based Fluid Boluses Clinical Diagnostic Criteria, Intramuscular Adrenaline Dosing, and Refractory Anaphylaxis 5-Minute Time-Critical Anticonvulsant Protocol and Status Epilepticus Care Common Toxidromes (Paracetamol, Iron, Caustics, Button Batteries) and Decontamination

5 Chapter 5: Paediatric Respiratory Medicine

Stridor Differential, Croup (Westley Score & Dexamethasone), and Epiglottitis RSV Pathogenesis, Supportive Management, Oxygen/High-Flow Criteria, and Futility of Bronchodilators/Steroids European/BTS Guidelines on Chronic Stepwise Control and Acute Severe Exacerbation Management Community-Acquired Pneumonia Etiology, Parapneumonic Effusion/Empyema, and Cystic Fibrosis Pulmonary Exacerbations

6 Chapter 6: Paediatric Cardiology

Acyanotic vs Cyanotic Congenital Heart Disease: Ductal Patency, Shunt Lesions, and Emergency Stabilization Paediatric Murmurs and Arrhythmias: Innocent vs Pathological Murmurs, SVT, and Resuscitation Protocols Acquired Heart Disease: Kawasaki Disease, Coronary Aneurysm Prevention, and Acute Rheumatic Fever

7 Chapter 7: Paediatric Gastroenterology, Hepatology & Nutrition

Dehydration Severity Assessment, Oral Rehydration Therapy (ORT), and Intravenous Fluid Protocols ESPGHAN Coeliac Diagnostic Criteria (Biopsy-Sparing Pathway) and Paediatric Crohn's/Ulcerative Colitis Breastfeeding, Formula Selection, Cow's Milk Protein Allergy (CMPA), GERD vs GOR, and Faltering Growth Prolonged Neonatal Jaundice Workup, Biliary Atresia Red Flags, and Acute Hepatitis/Liver Failure

8 Chapter 8: Paediatric Nephrology, Fluids & Electrolyte Balance

Paediatric UTI Diagnosis, Imaging Criteria (Ultrasound/DMSA/MCUG), and Vesicoureteral Reflux Minimal Change Nephrotic Syndrome (Steroid Regimen & Complications) vs Acute Post-Infectious Glomerulonephritis Paediatric AKI (pRIFLE/KDIGO), Haemolytic Uraemic Syndrome (HUS), and Hyperkalaemia/Dysnatraemia Management

9 Chapter 9: Paediatric Endocrinology & Inborn Errors of Metabolism

Paediatric DKA Protocol (ISPAD/European Fluid & Insulin Guidelines, Cerebral Oedema Prevention) and T1DM Maintenance Congenital Hypothyroidism Screening & Levothyroxine, Congenital Adrenal Hyperplasia (21-Hydroxylase Deficiency), and Adrenal Crisis Short Stature Workup, Precocious vs Delayed Puberty, and Approach to Suspected Inborn Errors of Metabolism (IEM)

10 Chapter 10: Paediatric Neurology, Neurodevelopment & Mental Health

Simple vs Complex Febrile Seizures, Childhood Epilepsy Syndromes (Absence, Infantile Spasms, Benign Rolandic), and Antiseizure Medications Red Flags for Raised Intracranial Pressure (ICP), Brain Tumours, Migraine vs Tension Headache Acute Bacterial Meningitis (LP Contraindications, Ceftriaxone, Dexamethasone) and Viral Encephalitis (Aciclovir) Developmental Milestones (Gross Motor, Fine Motor/Vision, Speech/Language, Social), Autism Spectrum, ADHD, and Cerebral Palsy

11 Chapter 11: Paediatric Haematology & Oncology

Microcytic Anaemia (Iron Deficiency vs Thalassaemia Trait/Mentzer Index), Haemolytic Anaemias (Spherocytosis, G6PD) Sickle Cell Crises (Vaso-occlusive, Acute Chest Syndrome, Stroke Prevention), Immune Thrombocytopenia (ITP), and Haemophilia A/B Acute Lymphoblastic Leukaemia (ALL), Neuroblastoma, Wilms Tumour, and Management of Febrile Neutropenia

12 Chapter 12: Paediatric Infectious Diseases, Immunology & Allergy

Common Childhood Exanthems: Clinical Morphology, Timelines, Complications, and Management Paediatric Tuberculosis, Sepsis Six in Children, and Acute Osteoarticular Infections Pediatric Allergy, Atopic Eczema, Food Hypersensitivity, and Desensitization Primary Immunodeficiencies, Warning Signs, Live Vaccine Contraindications, and European Immunisation Schedules

13 Chapter 13: Paediatric Musculoskeletal, Dermatology & Surgical Conditions

The Limping Child, Septic Arthritis vs Transient Synovitis, and Juvenile Idiopathic Arthritis Henoch-Schönlein Purpura, Kawasaki Disease vs MIS-C, Infantile Haemangiomas, and Common Pediatric Eruptions Acute Appendicitis, Intussusception, Pyloric Stenosis, Testicular Torsion, and Incarcerated Hernia

14 Chapter 14: Research Methods, Biostatistics & Evidence-Based Paediatrics

Study Designs, Causality, Bias, and Epidemiological Measures in Paediatrics Diagnostic Test Accuracy, Statistical Inference, and Hypothesis Testing Systematic Reviews, Meta-Analysis, Decision Analysis, and Paediatric Research Ethics

15 Chapter 15: Paediatric Ophthalmology & ENT Disorders

Paediatric Vision Assessment, Refractive Disorders, Strabismus, and Leukocoria Ocular Emergencies, Orbital Infections, ROP, and Systemic Manifestations Paediatric Otolaryngology: Otitis Media, Hearing Impairment, and Upper Airway Conditions

16 Chapter 16: Paediatric Sports Medicine & Musculoskeletal Health

Skeletal Maturity, Physeal Injuries, Apophysitis, and Overuse Syndromes Paediatric Sports Concussion, Second Impact Syndrome, and Return-to-Play Protocols Pre-Participation Screening, Physical Activity Guidelines, and Chronic Disease Clearance

17 Chapter 17: Adolescent Medicine & Healthcare Transition

Biopsychosocial Development, Pubertal Staging, and Adolescent Communication Adolescent Confidentiality, Risk Behaviours, Reproductive Health, and Eating Disorders Chronic Illness in Adolescence and Structured Healthcare Transition

18 Chapter 18: Paediatric Genetics, Dysmorphology & Clinical Genomics

Patterns of Inheritance, Non-Mendelian Mechanisms, and Pedigree Construction Clinical Dysmorphology, Chromosomal Aneuploidies, and Microdeletion Syndromes Genetic Testing Technologies, Prenatal Diagnosis, and Genetic Counselling Ethics

19 Chapter 19: Paediatric Mental Health, Behaviour & Community Medicine

Cognitive Development, Attachment, Screening, and Common Emotional Disorders Regulatory Disorders, Neurodevelopmental Behavioural Conditions, and Psychosomatic Illness Community Child Healthcare Structures, Disability Coordination, and Child Advocacy

Biopsychosocial Development, Pubertal Staging, and Adolescent Communication

Key Takeaways Explain This Topic AI

Adolescent development spans three distinct phases: early (10–13 years; concrete thinking, preoccupation with bodily changes), middle (14–17 years; emergence of abstract reasoning, peak peer orientation, experimentation), and late (18–21 years; stable identity consolidation, executive future planning, vocational autonomy).

Asynchronous neurodevelopment—characterized by early functional maturation of the socio-emotional limbic and striatal dopaminergic reward systems paired with protracted myelination of the prefrontal executive control network—underpins normative adolescent sensation-seeking and risk-taking.

Sexual Maturity Rating (SMR / Tanner staging) evaluates breast (B1–B5) and pubic hair (PH1–PH5) in females, and genitalia (G1–G5) and pubic hair in males; testicular volume ≥ 4 mL \ge 4\text{ mL} ≥ 4 mL measured by Prader orchidometer defines central male pubertal onset, while peak height velocity occurs early in females (Tanner B2–B3) and late in males (Tanner G4).

Delayed puberty is defined by the absence of breast thelarche by age 13 in females or testicular enlargement < 4 mL <4\text{ mL} < 4 mL by age 14 in males; clinical evaluation differentiates constitutional delay of growth and puberty (CDGP) from hypogonadotropic hypogonadism (functional, Kallmann syndrome) and hypergonadotropic hypogonadism (Turner syndrome 45,X, Klinefelter syndrome 47,XXY).

Effective adolescent practice uses youth-friendly communication, routine private time where appropriate, clear limits to confidentiality under national law and safeguarding duties, and the HEADSSS psychosocial domains: Home, Education, Eating, Activities, Drugs, Sexuality, Suicide and Safety.

Last updated: November 2026

Biopsychosocial Development, Pubertal Staging, and Adolescent Communication

Adolescence represents the dynamic biopsychosocial transition between childhood and adulthood. Far from being merely a period of physical growth, it encompasses profound neurodevelopmental remodeling, cognitive maturation, psychological individuation, and social role transition. Paediatricians must master both the biological milestones of puberty and the specialized communication skills required to engage young people during this vulnerable developmental window.

The Biopsychosocial Framework of Adolescence

Developmental psychologists and the European Academy of Paediatrics (EAP) categorize adolescence into three distinct, overlapping developmental stages. Each stage is characterized by unique cognitive patterns, emotional tasks, and interpersonal orientations.

Developmental Stage Typical Age Range Cognitive & Moral Development Somatic & Body Image Concerns Psychosocial & Peer Orientation Clinical Engagement Strategy

Early Adolescence 10–13 years Concrete operational thinking predominant; limited ability to extrapolate future consequences; binary ('black-or-white') moral concepts. Onset of secondary sexual characteristics; acute self-consciousness, preoccupation with bodily changes, anxiety regarding normality and peer comparison. Emotional dependence on family remains strong; peer relationships are primarily based on shared activities within same-sex groups. Focus on immediate present benefits; provide explicit reassurance regarding physical normality and bodily changes.

Middle Adolescence 14–17 years Emergence of formal operational thought ; capacity for abstract logic and hypothetical reasoning, though inconsistently applied under emotional arousal. Pubertal changes largely complete; peak concern regarding attractiveness; experimenting with personal style and physical presentation. Peak peer group influence ; conflict with parental authority as autonomy is asserted; experimentation with romantic attachments, sexuality, and risk-taking. Acknowledge emerging independence; emphasize confidential, non-judgmental dialogue; assist in evaluating immediate vs future consequences.

Late Adolescence 18–21 years Consolidated formal operational thought ; robust executive function, future-oriented planning, nuanced appreciation of moral complexity. Stable body image; acceptance of physical self and realistic somatic appraisal. Individual identity consolidation ; shift from peer crowd conformity to intimate dyadic relationships; focus on vocational, educational, and financial independence. Treat as an autonomous adult partner; foster long-term self-management, health maintenance, and life goals.

Neurobiology of the Adolescent Brain: The Dual-System Model

Historically, adolescent risk-taking was misattributed to cognitive deficits or willful rebellion. Contemporary developmental neuroscience demonstrates that adolescent behavior is driven by asynchronous neurodevelopment between distinct functional brain circuits—a paradigm formalized as the dual-system (or socio-emotional vs cognitive control) model . +--------------------------------------------------------------------------+

  • | ASYNCHRONOUS MATURATION OF THE ADOLESCENT BRAIN |
  • | |
  • | [ Subcortical Socio-Emotional & Limbic Network ] |
  • | - Structures: Amygdala, Ventral Striatum, Nucleus Accumbens |
  • | - Mediators: Dopaminergic & oxytocinergic surges |
  • | - Maturation: Rapid pubertal onset (11-15 years) |
  • | - Function: High sensation-seeking, reward sensitivity, peer reactivity|
  • | │ |
  • | ▼ TEMPORAL DEVELOPMENTAL MISMATCH |
  • | │ |
  • | [ Prefrontal Executive Cognitive Control Network ] |
  • | - Structures: Dorsolateral Prefrontal Cortex (DLPFC), VMPFC, ACC |
  • | - Mediators: Synaptic pruning, progressive axonal myelination |
  • | - Maturation: Protracted through mid-20s (~24-25 years) |
  • | - Function: Impulse inhibition, long-term risk appraisal, regulation |
  • +--------------------------------------------------------------------------+
  • Mechanisms of Asynchrony

Early Limbic Hyper-Responsiveness : Driven by rising pubertal sex steroids, subcortical dopaminergic reward pathways (ventral striatum and nucleus accumbens) undergo marked functional reorganization. Adolescents experience heightened neural reactivity to immediate rewards, novelty, and peer social status compared to both children and adults.

Protracted Prefrontal Myelination : The prefrontal cortex (PFC)—specifically the dorsolateral prefrontal cortex (DLPFC) and anterior cingulate cortex (ACC)—coordinates executive functions: response inhibition, working memory, emotional regulation, and future scenario evaluation. This region undergoes prolonged structural remodeling, including extensive synaptic pruning of unused connections and progressive axonal myelination that continues well into the third decade of life.

The 'Cold' vs 'Hot' Cognition Paradox : In calm, hypothetical laboratory conditions ('cold cognition'), middle adolescents evaluate risks as accurately as adults. However, in emotionally charged, high-arousal, or peer-present settings ('hot cognition'), the hyperactive socio-emotional network overpowers the still-maturing executive prefrontal network. From an evolutionary perspective, this sensation-seeking mechanism facilitated dispersal from the natal group and reproductive exploration, but in contemporary society, it underlies elevated risks of accidental injury, substance experimentation, and unsafe sexual encounters.

Pubertal Physiology and Tanner Staging (Sexual Maturity Rating)

Puberty is triggered by the reawakening of the hypothalamic-pituitary-gonadal (HPG) axis . Pulsatile secretion of Gonadotropin-Releasing Hormone (GnRH) from the hypothalamus stimulates the anterior pituitary to secrete Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) . Initially occurring exclusively during deep sleep, these gonadotropin pulses stimulate gonadal maturation, sex steroid synthesis (estradiol in females, testosterone in males), and the phenotypic emergence of secondary sexual characteristics.

Tanner Staging Criteria

The Sexual Maturity Rating (SMR) , developed by James Tanner, standardizes pubertal progression across five continuous morphological stages.

Female Pubertal Staging

Breast Development (B1–B5) :

B1 (Prepubertal) : Elevation of papilla only; no glandular breast tissue palpable.

B2 (Breast Bud / Thelarche) : Palpable firm subareolar bud beneath the papilla; slight enlargement of areolar diameter. Marks the first objective physical sign of central puberty in females (typically age 8.5–12.5 years).

B3 : Further enlargement of breast glandular tissue and areola without separation of their respective contours.

B4 (Secondary Mound) : Areola and papilla project above the surrounding contour of the breast tissue to form a distinct secondary mound.

B5 (Mature Adult Contour) : Recession of the areola to the general contour of the breast; papilla alone remains projected.

Female Pubic Hair (PH1–PH5) :

PH1 : Prepubertal; no pigmented sexual hair (vellus hair only).

PH2 : Sparse, lightly pigmented, straight or downy hair along the medial labia majora.

PH3 : Darker, coarser, and distinctly curlier hair spreading over the pubic symphysis.

PH4 : Adult-quality coarse hair covering the pubis but sparing the medial thighs.

PH5 : Adult inverse-triangle pattern with horizontal upper border and lateral extension to the medial thighs.

Male Pubertal Staging

Male Genital Development (G1–G5) :

G1 (Prepubertal) : Testicular volume < 4 mL <4\text{ mL} < 4 mL ; longitudinal testicular diameter < 2.5 cm <2.5\text{ cm} < 2.5 cm ; penis unchanged from early childhood.

G2 (Pubertal Onset) : Testicular enlargement to ≥ 4 mL \ge 4\text{ mL} ≥ 4 mL (or length ≥ 2.5 cm \ge 2.5\text{ cm} ≥ 2.5 cm ) measured using a Prader orchidometer; scrotal skin thins, reddens, and relaxes; minimal or no penile elongation. Marks the first objective physical sign of central puberty in males (typically age 9.5–13.5 years).

G3 : Further enlargement of testes ( 6 – 12 mL 6\text{--}12\text{ mL} 6 – 12 mL ) and scrotum; significant elongation of the penis.

G4 : Testicular volume 12 – 15 mL 12\text{--}15\text{ mL} 12 – 15 mL ; further penile growth with prominent enlargement of the glans and increased penile girth; darkening of scrotal rugae.

G5 (Mature Adult Genitalia) : Testicular volume > 15 mL >15\text{ mL} > 15 mL (normal adult range: 15 – 25 mL 15\text{--}25\text{ mL} 15 – 25 mL ); adult penile dimensions.

Male Pubic Hair (PH1–PH5) : Follows the same qualitative morphological stages as females, progressing from sparse hair at the base of the penis (PH2) to adult-quality pubic hair extending onto the medial thighs (PH5). +--------------------------------------------------------------------------+

  • | PRADER ORCHIDOMETER REFERENCE |
  • | |
  • | [ 1 - 3 mL ] Prepubertal childhood baseline |
  • | [ 4 mL ] CRITICAL THRESHOLD: Central pubertal onset (Tanner G2) |
  • | [ 6 - 10 mL ] Early-to-mid pubertal progression (Tanner G3) |
  • | [ 12 - 15 mL] Mid-to-late pubertal enlargement (Tanner G4) |
  • | [ 15 - 25 mL] Fully mature adult testicular volume (Tanner G5) |
  • +--------------------------------------------------------------------------+
  • Growth Spurt Kinetics and Somatic Landmarks

The timing of the pubertal growth spurt relative to secondary sexual characteristics exhibits a fundamental sexual dimorphism:

Females :

Peak Height Velocity (PHV) occurs early in puberty , typically during Tanner Stage B2 to B3 (mean age: 11.5 – 12.0 years 11.5\text{--}12.0\text{ years} 11.5 – 12.0 years ). Girls gain an average of 8.0 – 8.5 cm/year 8.0\text{--}8.5\text{ cm/year} 8.0 – 8.5 cm/year during peak linear growth.

Menarche is a late pubertal event, occurring approximately 2.0 to 2.5 years after thelarche (almost universally during Tanner Stage B4 , mean age: 12.5 – 13.0 years 12.5\text{--}13.0\text{ years} 12.5 – 13.0 years ). Menarche indicates that linear growth velocity is decelerating; girls typically gain only 4.0 – 7.0 cm 4.0\text{--}7.0\text{ cm} 4.0 – 7.0 cm of total linear height following menarche prior to complete epiphyseal fusion.

Males :

Peak Height Velocity (PHV) occurs late in puberty , typically during Tanner Stage G4 (mean age: 13.5 – 14.0 years 13.5\text{--}14.0\text{ years} 13.5 – 14.0 years ). Boys gain an average of 9.5 – 10.0 cm/year 9.5\text{--}10.0\text{ cm/year} 9.5 – 10.0 cm/year during peak linear growth.

Spermarche (conscious awareness of viable sperm release in first nocturnal emission/ejaculation) typically occurs earlier, during Tanner Stage G3 (testicular volume 10 – 12 mL 10\text{--}12\text{ mL} 10 – 12 mL ).

Important

Because peak linear growth occurs early in female puberty (Tanner B2–B3) and late in male puberty (Tanner G4), girls are temporarily taller and physically more mature than their male peers between ages 11 and 13. Reassuring boys and parents regarding this biological timeline prevents unnecessary anxiety over temporary somatic differences.

Delayed Puberty: Diagnostic Approach and Differential Diagnosis

Delayed puberty represents one of the most frequent endocrine presentations in adolescent medicine. Clinical evaluation requires distinguishing benign, self-limiting developmental variations from permanent neuroendocrine or gonadal failure.

Clinical Definitions

Females : Absence of breast budding (thelarche, Tanner B2) by 13 years , or no menarche by 15 years or within 3 years of thelarche .

Males : Failure of testicular volume to reach ≥ 4 mL \ge 4\text{ mL} ≥ 4 mL (Tanner G2) by 14.0 years of age , or failure to complete genital maturation within 4.5 years of pubertal onset.

Diagnostic Classification

Diagnostic Category Pathophysiology & Etiology Endocrine Profile Bone Age & Growth Velocity Clinical Distinguishing Features

Constitutional Delay of Growth and Puberty (CDGP) Temporary physiological delay in the maturation of the hypothalamic GnRH pulse generator. Most common cause (>60% in boys, ~30% in girls). Low baseline LH, FSH and sex steroids; GnRH responses may be blunted or appropriate and overlap with congenital hypogonadotropic hypogonadism. Delayed bone age (typically retarded > 2 years >2\text{ years} > 2 years relative to chronological age); growth velocity normal for bone age. Strong family history of late puberty ('late bloomers'); normal predicted adult height within mid-parental target range; completely benign prognosis.

Hypogonadotropic Hypogonadism (HH) (Secondary / Central Failure) Functional HH : Reversible central suppression secondary to chronic systemic illness (celiac disease, IBD, cystic fibrosis, chronic renal failure), severe malnutrition/anorexia, or Relative Energy Deficiency in Sport (REDs).; Permanent HH : Congenital GnRH deficiency (Kallmann syndrome: ANOS1/KAL1 , FGFR1 mutations; normosmic IHH), panhypopituitarism, or CNS tumors (craniopharyngioma, germinoma, pituitary adenoma). Low or inappropriately 'normal' LH and FSH in the presence of prepubertal sex steroid levels. Bone age delayed; the pubertal growth spurt is absent. Childhood growth can remain normal in isolated GnRH deficiency. Kallmann Syndrome : Anosmia or hyposmia on formal olfaction testing, bimanual synkinesia, high-arched palate, unilateral renal agenesis.; CNS Tumors : Headaches, visual field defects (bitemporal hemianopia), vomiting, diabetes insipidus.

Hypergonadotropic Hypogonadism (Primary Gonadal Failure) Intrinsic gonadal insensitivity or destruction. Loss of negative steroid feedback leads to massive pituitary gonadotropin hypersecretion.; Turner Syndrome (45,X) in females; Klinefelter Syndrome (47,XXY) in males; acquired post-chemotherapy (alkylating agents) or pelvic irradiation; autoimmune gonadal failure; bilateral mumps orchitis. Markedly elevated LH and FSH ; low sex steroids (estradiol or testosterone). Bone age delayed or normal; growth stunting prominent in Turner syndrome. Turner (45,X) : Short stature, webbed neck (pterygium colli), low posterior hairline, cubitus valgus, broad shield chest, bicuspid aortic valve, coarctation of aorta, streak ovaries.; Klinefelter (47,XXY) : Tall stature, eunuchoid proportions (arm span exceeds height by > 5 cm >5\text{ cm} > 5 cm ), small, firm, fibrotic testes ( < 4 mL <4\text{ mL} < 4 mL ), gynecomastia, learning/language difficulties.

  • Stepwise Investigation Pathway +--------------------------------------------------------------------------+
  • | INVESTIGATION ALGORITHM FOR DELAYED PUBERTY |
  • | |
  • | Initial Assessment: Detailed family history, growth velocity curves, |
  • | Prader orchidometry / Tanner SMR, systemic review (GIT, weight, smell) |
  • | │ |
  • | ▼ |
  • | First-Line Diagnostic Testing: |
  • | 1. Left hand and wrist radiograph (Bone Age: Greulich & Pyle) |
  • | 2. Serum baseline LH, FSH, Testosterone (male) or Estradiol (female) |
  • | 3. Systemic screen: ESR/CRP, complete blood count, celiac serology |
  • | (anti-tTG IgA), renal/hepatic panel, free T4, TSH, Prolactin, IGF-1 |
  • | │ |
  • | ┌─────────────────────┴──────────────────────┐ |
  • | ▼ ▼ |
  • | High LH / High FSH Low LH / Low FSH |
  • | (Hypergonadotropic) (Hypogonadotropic) |
  • | │ │ |
  • | ▼ ▼ |
  • | Karyotype Analysis: Evaluate Bone Age & Clues: |
  • | - 45,X: Turner Syndrome - Bone Age delayed, +family |
  • | - 47,XXY: Klinefelter Syndrome history, normal systemic |
  • | - Normal karyotype: Chemo, screen: Presumed CDGP. |
  • | radiation, autoimmune failure - Anosmia: Kallmann Syn. |
  • | - Visual deficit/headache: |
  • | Urgent Pituitary MRI. |
  • +--------------------------------------------------------------------------+
  • Clinical Management of CDGP

Reassurance and Surveillance : Because CDGP is a normal variant with excellent adult height outcomes, expectant observation with clinical monitoring every 6 months is standard.

Low-Dose Hormonal Priming : In adolescents ≥ 14 \ge 14 ≥ 14 years with severe psychological distress, low self-esteem, or peer bullying, a short course of low-dose sex steroids can be administered to stimulate secondary sexual characteristics and accelerate growth without inducing premature epiphyseal closure:

Males : Intramuscular testosterone enanthate or cypionate ( 50 – 100 mg 50\text{--}100\text{ mg} 50 – 100 mg monthly for 3 to 6 months).

Females : Low-dose oral micronized estradiol ( 0.25 – 0.5 mg 0.25\text{--}0.5\text{ mg} 0.25 – 0.5 mg daily) or transdermal estradiol patch ( 12.5 μ g/24h 12.5\text{ }\mu\text{g/24h} 12.5 μ g/24h ) for 3 to 6 months.

Adolescent Clinical Communication and the HEADSSS Framework

Consulting with adolescents requires deliberate adaptations of standard paediatric interview techniques. Adolescents are neither oversized children nor miniature adults; effective consultation balances parental involvement with the young person's emerging legal and developmental autonomy.

Structuring the Consultation: The Tripartite Interview

Joint Opening (3–5 minutes) : Welcome both the adolescent and parents. Review the agenda, confirm shared goals, and explain the structure of the visit.

Normalizing Private Time : Explicitly frame one-on-one time as routine practice for all adolescents: “In our clinic, starting at age 12, I spend dedicated private time alone with every young person. This gives us a chance to discuss health, school, and lifestyle topics confidentially, before welcoming parents back to review our overall plan together.”

Confidentiality and Its Limits : Establish the therapeutic alliance by clearly defining privacy boundaries before initiating sensitive questioning:

Confidentiality : Explain who may access clinical information and the protections and limits that apply under national law. Encourage appropriate family support without promising absolute secrecy.

Safety and Legal Limits : Relevant information may need sharing to prevent serious harm, address abuse or neglect, comply with law or a court order, or protect a young person who cannot decide about disclosure. For example, UK GMC guidance requires a proportionate case-by-case assessment, not an exhaustive three-event rule. Share the minimum necessary with appropriate people and document why. Normally explain the proposed disclosure first; omit advance warning if it would increase danger or undermine protection.

The HEADSSS Psychosocial Interview

The HEADSSS framework is the internationally recognized gold standard for adolescent psychosocial risk screening. It is conducted in a progressive sequence, moving from neutral, low-threat topics (Home, Education) to increasingly sensitive domains (Sexuality, Suicide). +--------------------------------------------------------------------------+

  • | THE HEADSSS SCREENING FRAMEWORK |
  • | |
  • | [H] Home: Family stability, emotional safety, household conflict |
  • | [E] Education & Employment: School performance, attendance, bullying |
  • | [E] Eating & Nutrition: Body satisfaction, restrictive eating, purging |
  • | [A] Activities & Peers: Extracurriculars, screen time, peer group |
  • | [D] Drugs & Substances: Alcohol, vaping, cannabis, illicit substances |
  • | [S] Sexuality & Identity: Attraction, sexual activity, contraception |
  • | [S] Suicide & Mental Health: Mood, anxiety, self-harm, sleep quality |
  • | [S] Safety: Cyberbullying, physical violence, seatbelts, exploitation |
  • +--------------------------------------------------------------------------+

Domain Specific Clinical Probing Questions Red Flag Findings

H — Home “Who lives at home with you? Who is your go-to person when you are stressed? Do you feel safe in your home?” Unstable housing, severe domestic conflict, lack of any supportive adult, physical or emotional abuse.

E — Education / Employment “How is school going? Have your grades changed recently? What do you enjoy most? Do you ever feel unsafe or picked on at school?” Sudden drop in academic performance, truancy/absenteeism, active bullying, cognitive decline.

E — Eating “What do you typically eat on an average day? Have you tried to change your weight recently? How do you feel about your body shape?” Severe dietary restriction, skipping meals, body dysmorphia, induced vomiting, binge eating, rapid weight loss.

A — Activities “What do you enjoy doing for fun outside of school? Who are your main friends? How much time do you spend on gaming or social media?” Total loss of interest in hobbies (anhedonia), social isolation, toxic peer crowd, screen use that disrupts sleep, schoolwork or relationships.

D — Drugs & Substances “Many young people your age experiment with alcohol, vaping, or cannabis. Have your friends tried these? Have you ever experimented yourself?” Solitary substance use, driving or riding with intoxicated drivers, polysubstance abuse, daily dependence.

S — Sexuality “Are you in a relationship or seeing anyone? Are you attracted to boys, girls, or both? Are you sexually active? What are you using for protection?” Unprotected intercourse, multiple partners without barrier protection, history of non-consensual sexual encounters, coercive control.

S — Suicide & Mood “Do you often feel down, depressed, or overwhelmed? Have you ever felt like life wasn't worth living? Have you ever harmed yourself or thought about ending your life?” Active suicidal ideation with plan and intent, recurrent superficial or deep cutting/burning, profound despair.

S — Safety “Do you always wear a seatbelt? Have you ever been in a vehicle with an intoxicated driver? Has anyone ever pressured you for explicit photos online?” Participation in high-risk reckless driving, online grooming, exposure to weapon violence, gang involvement.